protegrin-1 and Colitis

Infectious intestinal colitis, manifesting as intestinal inflammation, diarrhea, and epithelial barrier disruption, affects millions of humans worldwide and, without effective treatment, can result in death. In addition to this, the significant rise in antibiotic-resistant bacteria poses an urgent need for alternative anti-infection therapies for the treatment of intestinal disorders. Antimicrobial peptides (AMPs) are potential therapies that have broad-spectrum antimicrobial activity due to their (1) unique mode of action, (2) broad-spectrum antimicrobial activity, and (3) protective role in GI tract maintenance. Protegrin-1 (PG-1) is an AMP of pig origin that was previously shown to reduce the pathological effects of chemically induced digestive tract inflammation (colitis) and to modulate immune responses and tissue repair. This study aimed to extend these findings by investigating the protective effects of PG-1 on pathogen-induced colitis in an infection study over a 10-day experimental period. The oral administration of PG-1 reduced

Topics: Animals; Anti-Inflammatory Agents; Antimicrobial Cationic Peptides; Citrobacter rodentium; Colitis; Colon; Cytokines; Disease Models, Animal; Enterobacteriaceae Infections; Female; Inflammation; Intestinal Mucosa; Intestines; Mice; Mice, Inbred C57BL; Pore Forming Cytotoxic Proteins